83-5959-79　Adalimumab Biosimilar, TNF alpha 1mg　587095

特徴

• Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNF alpha, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.
• Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNF alpha) plays important roles in the regulation of immune cells.
• As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells.
• Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.